Low molecular weight heparin in atrial fibrillation prior to cardioversion: Short-term safety and efficacy in a transesophageal echocardiography prospective study  by Djaouti, Lydia et al.
462A ABSTRACTS - Noninvasive Imaging 
1214 
POSTER SESSION 
Left Atrial Structural and Functional 
Abnormalities: Echocardiographic 
Insights 
Tuesday, April 01, 2003, 3:00 p.m.-500 p.m. 
McCormick Place, Hall A 
Presentation Hour: 4:00 p.m.-500 p.m. 
1214-33 Safety of Low Molecular Weight Heparin After 
Transesophageal Echocardiographic Guided 
Cerdioversion as Bridging Therapy 
Deborah A. Hushes. Joseph F. Malouf, Brenda S. Moon, Naser A. Ammash, Paul A. 
Friedman, Krishnawaramy Chandrasedaran, Bernard J. Gersh, Mayo Clinic, Rochester, 
w 
Background: In patients undergoing transesophageal echocardiographic (TEE) guided 
cardioversion for atrial fibrillation of unknown or > 46 hours duration, the safety of post- 
cardioversion subcutaneous (sq) low molecular weight heparin (LMWH), in lieu of intra- 
venous unfractionated heparin, as bridging therapy until warlarin anticoagulation is thera- 
peutic (INR 2-3) is unclear. 
Methods: The Cardioversion Data Base from May 2000 through August 2002 was 
searched for patients dismissed home after successful TEE guided cardioversion on 
fixed doses of LMWH because of a sub-therapeutic INR. Patients wars followed up 
through clinical record review to identify any bleeding or cardioembolic events while on 
LMWH. 
Results: Eighty-one cases met our inclusion criteria and had complete follow up data (60 
men, 21 women; mean age 67 years +I- 13: 11 patients > 79 years). Eleven patients 
(13%) had a serum creatinine > 1.5 mg/dL. Eighteen patients received Ardeparin (130 U/ 
kg subcutaneously (sq) every twelve hours (ql2h). 14 received Enoxaparin (1 mgIkg sq 
q12h) and 45 received Dalteparin (100 U/kg sq q12h). Forty-nine patients had main- 
tained sinus rhythm at follow up (mean of 81 days). Bleeding complications occurred in 5 
patients (6.2%), all of whom were greater than 79 years old, comprising 45% of all 
patients in this age group. Three were major bleeds (two gastrointestinal and one retro- 
peritoneal) requiring hospitalization and blood transfusion. The INR was supra-therapeu- 
tic in one. Two were minor bleeds requiring no therapy. None had a serum creatinine > 
1.5 mg/dL. No patient experienced stroke or other systemic embolism while using 
LMWH. 
Conclusion: In this small cohort, no strokes or other systemic embolic events were 
observed in association with LMWH at doses used to treat acute deep venous thrombo- 
sis or pulmonary embolism. However, five bleeding complications ware observed in 
patients > 79 years of age. More data are needed. 
1214-34 Low Molecular Weight Heparin in Atrial Fibrillation Prior 
to Cardioversion: Short-Term Safety and Efficacy in a 
Transesophegeal Echocardiography Prospective Study 
Lydia Djaouti, Charles Smadja, Nadia Benyounes, Catherine Albo, Olivier Belliard. 
Franck Boccara. Ariel A. Cohen, Saint Antoine University, Paris, France 
Conventional treatment using wariarin (W) in atrial fibrillation (AF) before cardioversion is 
associated with a decreased thromboembolic (TE) risk. Currently, no echocardiographic 
study has been performed to evaluate the frequency of transoesophageal (TEE) TE risk 
markers under chronic W. We aimed at comparing TE markers in AF of > 2 days under 
W or low molecular weight heparin treatment (LMWH). 
Methods : Using transthoracic echocardiography and TEE, before cardioversion. wa 
compared 66 consecutive patients (Pts) under chronic W therapy (at least 3 weeks and 
INR > 2) to 140 consecutive Pts treated with subcutaneous weight adjusted LMWH 
(dalteparin) for instantaneous anticoagulation prior to cardiovewon. The following echo 
parameters were recorded : left (I-AA) and right (RAA) atrial appendage areas, spontane- 
ous echo contrast (SEC) and thrombus (Thr). 
Results : No difference was observed in the 2 groups with regard to age (66 f 12 and 70 
* 12 years, respectively), previous TE event (16 % and 9 %, respectively, p = 0.220) and 
cardiovascular risk factors. Valvular disease was more frequent in the W group (41 .I % 
and 16.5 %, respectively, p < 0.001). A comparison of the 2 groups is shown in the table. 
AFlWarfarin AFrLMWH P 
(n = 66) (n=140) 
In-hospital TE event 0 0 
LAA area (cm&#1 76;) 5.36 * 2.43 5.93 f 2.54 0.139 
LA SEC (n, %) 39 (57.3) 65 (60.7) 0.754 
RA SEC (n. %) 6 (11.7) 32 (22.6) 0.086 
LAA thrombus (n, %) 2 (2.9) 6 (4.2) 0.929 
Conclusion : No in-hospital TE event was observed. Embolic risk markers are present in 
chronic W group as well as in LMWF group. The prasancs of LAA Thr under W therapy 
suggests the need for TEE before cardioversion to exclude the presence of atrial 
thrombus in high risk Pts. 
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1214-35 Thromboembolic Risk Stratification Based on SPAF 
Clinical Criteria in Patients With Paroxysmal Atrial 
Fibrillation and Flutter: A Prospective Transesophageal 
Echocardiography Study 
Nadia Benyounes. Lydia Djaouti, Charles Smadja. Catherine Albo. Olivier Bell&d, 
Franck Boccara, Ariel A. Cohen. Saint Antoine University, Paris, France 
It has been reported that patients (Pts) with paroxysmal atrial fibrillation and flutter (PAT) 
have a lower thromboembolic (TE) risk than those with permanent atrial fibrillation (AF). 
However, a recent longitudinal study suggested a similar annual rata of ischemic stroke 
in both populations. This apparent discrepancy could be explained by differences in the 
frequency of transesophageal echocardiography (TEE)-detected TE risk markers. 
Objective: We sought to assess TE risk markers using TEE in Pts with PAT according 
to the SPAF clinical criteria for risk stratification. 
Methods : As part of an ongoing study based on transthoracic and TEE in atrial arrhyth- 
mia, we prospectively studied 145 Pts within 46 hours of spontaneous cardioversion of 
any documented PAT (AF in 120 pts, atrial flutter or tachycardia in 25 Pts). Pts ware 
divided into high, moderate and low clinical risk groups. The following parameters ware 
evaluated : left atrial (LA) and LA appendage (LAA) areas, spontaneous echo contrast 
(SEC), LAA end diastolic emptying velocity (Vel), LAA thrombus (Thr) and thoracic aorta 
atheroma (TAA). 
Results : The main results are summarised in the table. 
Mean age (years) 
LA area @ml;) 
LAA area @I+;) 
LAA Vel 95 cm/s (II,%) 
LA SEC (II,%/.) 
LAA Thr (II,%) 
TAA -> 4mm (II,%) 
High risk Moderate risk Low risk P 
(rl=66) (n=34) (rl=45) 
77.9 * 9.9 63.6 -t 7.3 54.2 zt 15.3 <O.OOl 
19.9 * 5.6 19.3 * 4 18.3 * 5.5 0.937 
4.9 * 2.3 4.4* 1.7 4.6 + 1.9 0.987 
13 (20.6) IO (29.4) 13 (30) 0.460 
22 (35) 5 (15.1) 5(11.6) 0.007 
2 (3) 0 1 (2.2) 0.599 
15 (22.7) 5 (14.7) 2 (4.4) 0.031 
There was no difference in the 3 groups with regard to LA and LAA areas, Vel and Thr. 
,LA SEC and TAA wars significantly more frequent in high risk Pts using SPAF clinical 
criteria. 
Conclusion : These results suggest the need for a similar risk stratification and 
anticoagulant regimen in high-risk patients with PAT and permanent AF. 
1214-36 Recurrent lschemic Cerebral Events in Patients With 
Different Subtypes of Arterial or Cardiac Source of 
Embolism: A Four and Five-Year Follow-Up Study 
Stefano De Castro, Mauri& Rasura, llaria Passaseo, Filomena Di Lisl, Emanuele Di 
Angelantonio, Rosalba Patella, Alessandro Aiello, Francesco Fed&s, La Sapienza 
University, Rome, Italy 
Background This study was performed to assess the risk of recurrent ischemic events 
or death in stroke patients with different subtypes of arterial or cardiac source of embo- 
lism. 
Methods All patients admitted to the Department of Neurological Sciences underwent 
general medical and neurological examination, chest radiography, general blood chemis- 
try assay, CT scan, carotid ultrasound and transesophageal echocardiography. Patients 
discharged from the hospital have been followed-up for 5 years by clinical examination 
and telephone interview. In according to the modified criteria of Amarenco we divided 
patients in: Group I, those with a definite or possible arterial or cardiac source of embo- 
lism; Group II, with small-vessel disease; Group Ill, who could not be classified into either 
of the above groups. For the purpose of our study, Group I was further divided in patients 
with carotid artery disease, and definite, probable or possible source of emboksm (SOE). 
Results226 patients, mean age 55+17, male 51%, ware classified as follow: 152 (67%) 
in Group I, 60 (26%) in Group II and 16 (7%) in Group III. Overall recurrent stroke or 
death occurred in 34 (22%), 5 (6%) and 1 (6%) respectively in each group. 
During the observation period in Group I (mean age 57+17, male 51%) the recurrent 
rates was 43% for patients with definite, 17% for patients with probable, 20% for patients 
with possible causes of source of embolism and 21% for those with carotid artery dis- 
ease. In particular the highest recurrent rates of embolic events or death was observed in 
12 out of 27 (44%) patients with complicated aortic plaques and 12 out of 62 (19%) with 
atrial septal abnormalities determining right-to-left shunt. Conclusions: Patients with 
complicated aorta plaques on transesophageal echocardiography study are at increased 
risk for recurrence stroke or death. It suggests that these patients need a more aggras- 
sive treatment as opposed to those affected by other causes of ischemic stroke. 
1214-37 Predictors of Six-Month Sinus Rhythm Maintenance 
Following Successful Cardioversion of Atrial 
Fibrillation: An ACUTE Trial Ancillary Study 
John A. Sallach. Richard A. Grimm, Elizabeth Lieber, Carolyn Apperson-Hansen, Susan 
E. Jasper, Allan L. Klein, The Cleveland Clinic Foundation, Cleveland, OH 
Background: Clinical and transesophageal echocardiography (TEE) predictors of sinus 
rhythm (SR) maintenance following cardioversion of atrial fibrillation (AF) are poorly 
defined. The purpose of this study was to identify predictors of long-term SR mainte- 
nance following successful AF cardioversion. 
Methods: The Assessment of Cardioversion Using Transesophageal Echocardiography 
(ACUTE) Trial, randomized 1,222 patients with AF to TEE-guided cardioversion or con- 
ventional treatment. Successful conversion to SR occurred in 327 of 425 (60%) patients 
